NewAmsterdam Pharma Warrant
NAMSW
9 hedge funds and large institutions have $29.9M invested in NewAmsterdam Pharma Warrant in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 3 reducing their positions, and 1 closing their positions.
35% more capital invested
Capital invested by funds: $22.2M → $29.9M (+$7.68M)
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.03% less ownership
Funds ownership: 28.25% → 28.22% (-0.03%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$390K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$285K |
| 2 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
-$6.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.88K |
| 4 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$25 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FLSM
1
Frazier Life Sciences Management
Palo Alto,
California
| $11.5M | – | – | – |
|
|
RCM
2
RA Capital Management
Boston,
Massachusetts
| $7.67M | – | – | – |
|
|
AAA
3
Affinity Asset Advisors
New York
| $5.63M | – | – | – |
|
|
BCLSI
4
Bain Capital Life Sciences Investors
Boston,
Massachusetts
| $2.3M | -$25 | -1 | -0% |
|
|
DM
5
Deerfield Management
New York
| $2.13M | – | – | – |
|
|
AC
6
Aristeia Capital
Greenwich,
Connecticut
| $397K | +$390K | +15,708 | New |
|
|
VI
7
Vestcor Inc
Fredericton,
New Brunswick, Canada
| $239K | – | – | – |
|
|
8
CIBC Private Wealth Group
Atlanta,
Georgia
| $25.3K | -$6.2K | -250 | -20% |
|
|
9
UBS Group
Zurich,
Switzerland
| $9.27K | -$2.88K | -116 | -23% |
|
|
LCM
10
Laurion Capital Management
New York
| – | -$285K | -16,666 | Closed |
|
NAMSW Hedge Fund Activity: Q4 2025 in Review
9 of the 8,235 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma Warrant (NAMSW) for Q4 2025, worth a combined $29.9M — up 35% from $22.2M a quarter earlier.
Fund positioning in NAMSW was balanced in Q4 2025: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 3 trimmed.
The largest buyer was Aristeia Capital, opening a new position worth an estimated $390K. The largest seller was Laurion Capital Management, exiting entirely with an estimated $285K sold.
- 9 institutional investors held NewAmsterdam Pharma Warrant (NAMSW) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $29.9M of NewAmsterdam Pharma Warrant stock for Q4 2025, up 35% quarter-over-quarter.
- 1 fund opened new NewAmsterdam Pharma Warrant positions in Q4 2025 and 1 closed out, a net change of 0 holders.
- The largest NewAmsterdam Pharma Warrant buyer in Q4 2025 was Aristeia Capital, an estimated $390K added.
- The largest NewAmsterdam Pharma Warrant seller in Q4 2025 was Laurion Capital Management, an estimated $285K sold.
Based on aggregated 13F filings for Q4 2025.